Actinium Pharmaceuticals, Inc (ATNM) is a publicly traded Healthcare sector company. As of September 10, 2026, ATNM trades at $1.28 with a market cap of $38.67M and a P/E ratio of -1.17. ATNM moved +6.50% today. Year to date, ATNM is -4.38%; over the trailing twelve months it is -18.63%. Its 52-week range spans $0.74 to $2.41. Analyst consensus is buy with an average price target of $3.50. Rallies surfaces ATNM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for ATNM combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $1.28 |
| Market Cap | $38.67M |
| P/E Ratio | -1.17 |
| EPS | $-1.09 |
| Dividend Yield | 0.00% |
| 52-Week High | $2.41 |
| 52-Week Low | $0.74 |
| Volume | 221.92K |
| Avg Volume | 0 |
| Revenue (TTM) | $90.00K |
| Net Income | $-33.89M |
| Gross Margin | 0.00% |
2 analysts cover ATNM: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $3.50.